Studies investigating the prevalence of psychiatric disorders among trans individuals have identified elevated rates of psychopathology. Research has also provided conflicting psychiatric outcomes following gender-confirming medical interventions. This review identifies 38 cross-sectional and longitudinal studies describing prevalence rates of psychiatric disorders and psychiatric outcomes, pre- and post-gender-confirming medical interventions, for people with gender dysphoria. It indicates that, although the levels of psychopathology and psychiatric disorders in trans people attending services at the time of assessment are higher than in the cis population, they do improve following gender-confirming medical intervention, in many cases reaching normative values. The main Axis I psychiatric disorders were found to be depression and anxiety disorder. Other major psychiatric disorders, such as schizophrenia and bipolar disorder, were rare and were no more prevalent than in the general population. There was conflicting evidence regarding gender differences: some studies found higher psychopathology in trans women, while others found no differences between gender groups. Although many studies were methodologically weak, and included people at different stages of transition within the same cohort of patients, overall this review indicates that trans people attending transgender health-care services appear to have a higher risk of psychiatric morbidity (that improves following treatment), and thus confirms the vulnerability of this population.
Keywords: Gender dysphoria; anxiety; depression; mental health; psychiatric disorders; transsexualism.
Ibrahim C, Haddad R, Richa S. Ibrahim C, et al. Encephale. 2016 Dec;42(6):517-522. doi: 10.1016/j.encep.2016.02.011. Epub 2016 Mar 24. Encephale. 2016. PMID: 27017319 French.
Brown GR, Jones KT. Brown GR, et al. LGBT Health. 2016 Apr;3(2):122-31. doi: 10.1089/lgbt.2015.0058. Epub 2015 Dec 16. LGBT Health. 2016. PMID: 26674598
Nieder TO, Briken P, Richter-Appelt H. Nieder TO, et al. Psychother Psychosom Med Psychol. 2014 Jun;64(6):232-45. doi: 10.1055/s-0033-1336970. Epub 2014 Jun 3. Psychother Psychosom Med Psychol. 2014. PMID: 24892869 German. No abstract available.
Connolly MD, Zervos MJ, Barone CJ 2nd, Johnson CC, Joseph CL. Connolly MD, et al. J Adolesc Health. 2016 Nov;59(5):489-495. doi: 10.1016/j.jadohealth.2016.06.012. Epub 2016 Aug 17. J Adolesc Health. 2016. PMID: 27544457 Review.
Kyriakou A, Nicolaides NC, Skordis N. Kyriakou A, et al. Acta Biomed. 2020 Mar 19;91(1):165-175. doi: 10.23750/abm.v91i1.9244. Acta Biomed. 2020. PMID: 32191677 Free PMC article. Review.
Stelmar J, Victor R, Yuan N, Smith SM, Mallavarapu S, Sandhu S, Garcia MM. Stelmar J, et al. Sex Med. 2024 Aug 29;12(4):qfae048. doi: 10.1093/sexmed/qfae048. eCollection 2024 Aug. Sex Med. 2024. PMID: 39211910 Free PMC article.
Locke ER, Highland KB, Thornton JA, Sunderland KW, Funk W, Pav V, Brydum R, Larson NS, Schvey NA, Roberts CM, Klein DA. Locke ER, et al. JAMA Pediatr. 2024 Aug 19:e242835. doi: 10.1001/jamapediatrics.2024.2835. Online ahead of print. JAMA Pediatr. 2024. PMID: 39158896
Li J, Jin Y, Xu S, Wilson A, Chen C, Wang Y. Li J, et al. Int J Transgend Health. 2024 Mar 12;25(3):456-470. doi: 10.1080/26895269.2023.2273360. eCollection 2024. Int J Transgend Health. 2024. PMID: 39055632
Wolfe HL, Vimalananda VG, Wong DH, Reisman JI, Rao SR, Shipherd JC, Blosnich JR, Livingston NA, Jasuja GK. Wolfe HL, et al. Transgend Health. 2024 Apr 3;9(2):151-161. doi: 10.1089/trgh.2022.0040. eCollection 2024 Apr. Transgend Health. 2024. PMID: 38694620
Turan Ş, Özulucan MT, Karataş U, Kavla Y, Koyuncu O, Durcan E, Durcan G, Bağhaki S. Turan Ş, et al. Qual Life Res. 2024 Jul;33(7):1937-1947. doi: 10.1007/s11136-024-03664-6. Epub 2024 Apr 24. Qual Life Res. 2024. PMID: 38656406 Free PMC article.